Multifunctional topical formulation for the treatment of acne vulgaris and other skin conditions

ABSTRACT

A two-part aqueous composition for treating skin ailments, such as acne vulgaris, includes an acidic part having salicylic acid and an α-hydroxy acid, and an alkaline part having an alkaline nitrite salt. The α-hydroxy acid is preferably glycolic acid, lactic acid, malic acid, mandelic acid or a combination thereof. The alkaline nitrite salt is preferably sodium nitrite. The acidic part and the alkaline part are an acidic aqueous solution and an alkaline aqueous solution, respectively, which may either be mixed with one another then applied to an affected portion of a patient&#39;s skin or, alternatively, may be sequentially applied to the affected portion of the patient&#39;s skin, preferably within 15 minutes of one another.

CROSS-REFERENCE TO RELATED APPLICATION

The inventor claims domestic priority, pursuant to 35 U.S.C. §119(e) onthe basis of U.S. Provisional Patent Application No. 61/460,940, filedJan. 11, 2011, the entire disclosure of which shall be deemed to beincorporated by reference herein.

BACKGROUND OF THE INVENTION

1. Technical Field of the Invention

The present invention relates, generally, to an aqueous composition withan enhanced efficacy in the treatment of acne vulgaris (i.e., commonacne) and other skin conditions.

More particularly, the present invention relates to a multifunctionaltwo-part liquid formulation that, upon combination of both phases,either initially ex-vivo or on the skin after sequential application ofthe two parts, creates a mixture of at least three beneficial acidicsubstances. These compositions are a complex of various powerfulantimicrobial and keratolytic agents, where several of the acidsubstances serve more than one of these functions.

More specifically, the two-part liquid may be applied sequentially tothe subject's skin with either part first applied, or the topicalformulation may be applied to the subject's skin after the two partshave been combined. Each of the three alternate methods of applicationhas certain advantages.

2. Description of the Prior Art

The inventive method and composition are directed to the treatment of anumber of topical afflictions that heretofore have not been treatable bya multi-functional formulation and often not effectively treatable byany medication or other means. The areas in which this technology canfind application includes the broad range of topical skin infections anddisinfection, as well as conditions which involve both pathogenicmicroorganisms and physiologic dysfunction, and often a combination ofboth. In the latter category is the affliction termed acne, technicallyacne vulgaris, or common acne.

Acne is a common skin disease that is characterized by areas of skinwith seborrhea (scaly red skin), comedones (blackheads and whiteheads),papules (pinheads), pustules (pimples), nodules (large papules) andoften scarring. Acne affects mostly skin with the densest population ofsebaceous follicles; these areas include the face, the upper part of thechest, and the back. In most cases, acne is an inflammatory condition,but it can also be manifest in non-inflammatory forms. The lesions arecaused by hormonal stimulation of the skin's pilosebaceous units, skinstructures consisting of hair follicles and their associated sebaceousglands. Increased activity of those gland results in an enhancedsecretion of an oily/waxy matter, called sebum, which ordinarilyfunctions to lubricate the skin and hair. Although the primary cause ofacne is hyperactivity of the sebaceous gland, it is well recognized thata specific gram-positive microorganism, Propionibacterium acnes, isinvariably found in large numbers on the skin of acne sufferers. Itlives on the fatty acids in sebum, so the greater the amount of sebum,the greater the quantities of the organism that will be found. It isknown that this anaerobic (aerotolerant) bacterium generates enzymesthat degrade skin, and also creates proteins that may activate theimmune system.

The topical treatment of acne generally involves a material directed tothe control of the inflammatory aspect of the condition or thecharacteristic microorganism (P. acnes) that is present on the skin atlevels in excess of normal as a result of the excess sebum “feedstock.”A long-popular component of many topical acne medications is the R_(x)ingredient benzoyl peroxide. Major factors contributing to its efficacyis its skin-irritating capacity and its capacity to help rid thefollicles of excess dead skin cells. This lessens the chance of poreblockage. It has also been theorized to introduce oxygen into the pore,which is anathema to the anaerobic P. acnes. It is not, per se, anantimicrobial agent, as are some of the other topical R_(x) antibioticsthat are employed in the treatment of acne, e.g., clindamycin anderythromycin. The latter, of course, have no keratolytic effect, i.e.,the ability to “dissolve” skin cells, breaking the thin skin barriersthat cover the comedones, papules, pustules and nodules, and entrap thesebum, which lead to inflamed skin tissue.

The topical retinoid medicines, such as tretinoin, adapalene andtazarotene, are prescription drugs. They have desquamatory effects onthe superficial skin layers, promoting drainage of the comedones,papules, etc., which characterize the disease. These topical retinoidsmay cause mild to moderate irritation in some patients. Although theyhave no direct antimicrobial activity, these R_(x) drugs can exert someindirect activity by virtue of the fact that their actions render thefollicular microclimate (biofilm) less hospitable to P. acnes.

The most common material used for the treatment of acne is salicylicacid. This material, a so-called β-hydroxy acid, has recognizedkeratolytic activity, as do many so-called α-hydroxy acids (“AHAs”; theα-prefix is a measure of the distance of the carbon-bearing hydroxylgroup from the terminal carboxylic acid group.) Salicylic acid can“dissolve” skin tissue overlying the papules, pustules, etc., associatedwith the acne condition. In so doing, it promotes drainage of theblocked sebaceous glands and reduces the resulting inflammatorypotential. Associated with the keratolytic activity of salicylic acid isa recognized skin irritancy. The FDA, in its “monograph” on acceptedacne materials, allows salicylic acid to be used in acne medications atlevels no greater than 2.0%. Obviously, the higher the level, thegreater the potential for irritation. Alpha-hydroxy acids are alsokeratolytic, and to varying degrees have the ability to “dissolve” skintissue, depending upon the nature of the acid. The most commonly usedare glycolic acid and lactic acid. Others found in skin-care productsare malic acid, citric acid and tartaric acid and, the recent addition,mandelic acid. Because of concerns over the side effects of certaincommon α-hydroxy acids, in 1997, the FDA specified that the specificglycolic and lactic AHA concentrations in the product be 10% or less,its pH be 3.5 or higher, and it must have an effective sunscreen in theformulation or warn people to use sunscreen products.

Finally one additional R_(x) product has been accepted by the FDA fortreatment of acne, specifically azelaic acid. It is generally used totreat mild to moderate acne, as both a moderate antibacterial and ananti-inflammatory agent. Interestingly, it doesn't work well for acnethat isn't infected with bacteria. Studies show that azelaic acid worksas well as other topical R_(x) formulations (containing such R_(x)actives as benzoyl peroxide, tretinoin and antibiotics). But it has beenreported to take one to two months after starting the application oftopical azelaic acid compositions for the acne lesions to startdisappearing.

It should be particularly noted that the materials cited above, for thetreatment of acne, which are particularly effective, and with theexception of benzoyl peroxide, are all R_(x) formulations. And evenamong those that are FDA approved, no component of any of the foregoingformulations is particularly noteworthy for its antimicrobialproperties.

Relevant prior art known to the inventor, which addresses the foregoingprior art formulations and treatments, are Yu et al., U.S. Pat. No.4,105,782, issued Aug. 8, 1978; Warshaw, U.S. Pat. No. 4,450,175, issuedMay 22, 1984; Song et al., U.S. Pat. No. 5,843,998, issued Dec. 1, 1998;Gross, U.S. Pat. No. 8,017,138 B2, issued Sep. 13, 2011; Bernstein, U.S.Patent Application Publication No. 2005/0084509 A1, issued Apr. 21,2005; Peters, U.S. Patent Application Publication No. 2008/0311163 A1,issued Dec. 18, 2008; Cunliffe, William J., Acne, Martin Dunitz Ltd.,London (1989); and, 21 C.F.R. Part 333, “Topical Acne Drug Products forOver-the-Counter Human Use,” §333.310, disclosing acne activeingredients.

The composition of the present invention is a result of a search for acombination of agents which will provide the high-level antimicrobialactivity lacking in the above commercial formulations, while alsoproviding a keratolytic composition that is less irritating than thecommercial compositions currently available. And if such a compositioncould be discovered, it could well have a positive impact on a host ofother skin afflictions where microbial proliferation is a major problem.For example there are a number of bacterial skin infections andconditions, such as boils, folliculitis, carbuncles, furuncles,cellulitis, abscesses, impetigo, and erysipelas, where a powerfultopical antibacterial composition could be decidedly beneficial. Thesame can apply to common fungal infections, including athlete's foot,jock itch, ringworm, and yeast infections.

SUMMARY OF THE INVENTION

It is, therefore, an object of the present invention to provide amulti-functional composition directed to the treatment of acne vulgaris(acne) and other skin afflictions.

It is a further object of the invention to provide multiple keratolyticand germicidal agents for use in such treatment.

It is, yet, a further object of the invention to provide compositionscontaining multiple keratolytic and germicidal agents, whereby at leastone of the antimicrobial agents is created by combining two parts of thepresently claimed composition, so that acidification of a nitrite saltin one part of the composition results in the formation of nitrous acid,which exhibits a great germicidal rapidity against a broad spectrum ofbacteria and fungi.

It is an additional object of the present invention is to supplement thegermicidal activity of the two-part system of the inventive compositionthrough inclusion of mandelic acid, a known keratolytic acid, whosepowerful germicidal activity, particularly against the P. acnesbacterium, has heretofore not been taught as part of a method for thetreatment skin ailments, which combines keratolytic and germicidalproperties.

It is a further object of the present invention is provide for theapplication of the inventive composition by a variety of methods, forexample, either by initial mixing of individual precursor parts of thecomposition prior to application, or by individual ad seriatimapplication of each of the two parts, in either sequence, to accomplishspecific treatment goals.

The foregoing and related objects are accomplished by the topicalcomposition of the present invention, which is prepared by combining twoindividual precursor aqueous compositions (a term including gels andcreams), the Acid (A) and Base (B) phases, by either of two methods:

a) directly prior to topical application of their mixture, or

b) as an on-the-skin sequential application, by comingling the appliedfluids following their individual sequential application to thesubject's skin, either A→B, or B→A.

In the latter mode, the individual aqueous systems can be applied to thesubject at an interval of up to 15-minutes between applications, suchthat each aqueous solution's components may react with the components ofthe other aqueous system, to create the panoply of active agents. Theinventive composition, upon mixing in either manner, includes:

1) two keratolytic agents, i.e., the β-hydroxy salicylic acid and anα-hydroxy acid, wherein the latter, in a preferred embodiment, ismandelic acid. These acids are incorporated into the Acid (A) phase;and,

2) antimicrobial agents (Mandelic and Nitrous acids.)

-   -   a) Mandelic acid—Mandelic acid, in a preferred embodiment, in        addition to its keratolytic property, possesses significant        germicidal activity. With respect to antimicrobial activity as        provided by the A phase components, per se, while salicylic acid        is generally recognized as a mild antibacterial agent, mandelic        acid is by far the most powerful of all the α-hydroxy acids. To        put this into perspective, lactic acid has been shown to be a        stronger antimicrobial acid than all the common α-hydroxy acids,        with the exception of mandelic acid. The inventor has shown, in        earlier studies, that while lactic acid surpasses the        germicidally-effective α-hydroxy acid malic acid by killing        500-times more of the pathogenic organism E. coli within        30-seconds of contact, mandelic acid surprisingly kills        3000-times more of that organism than does even lactic acid        under the same conditions. And with respect to malic acid,        mandelic acid destroys 1.5 million times more E. coli cfu in        that same time frame. Mandelic acid is structurally similar to        lactic acid, except that the α-methyl group in lactic acid is        replaced by a phenyl group in mandelic acid. The phenyl group        makes mandelic acid more lipophilic, so that it is more        attracted to the lipids in bacterial and fungal cell walls, as        well as to the lipids of the skin, to which has a great        affinity. The latter quality enhances both the germicidal and        keratolytic efficacies of mandelic acid. Additional keratolytic        α-hydroxy acids, such as lactic and glycolic acid, may be        further used in the inventive composition. Their presence may        also help buffer the pH of the Acid (A) phase.    -   b) Nitrous Acid. The Base (B) phase, of the inventive        composition, includes a nitrite salt. This compound is the        source of significant further germicidal activity of the mixed        composition upon acidification by Phase A, whereby a major        portion of the nitrite ion is transformed to nitrous acid. This        is a remarkably effective antimicrobial material, which        surpasses even that of mandelic acid, by a substantial margin.        The highly-efficient nitrous acid antimicrobial is formed, to a        fractional degree, from the acidification of the nitrite ion (in        part B of the two-part composition) by H⁺ ions generated by the        partial ionization of both salicylic and mandelic acids in the        phase A; and preferentially by even stronger H⁺ ion donors, such        as phosphoric, citric and/or hydrochloric acids. The latter may        be included in Phase A of the composition, to spare consumption        of H⁺ ions from salicylic and the α-hydroxy acids, through        acidic transformation of the nitrite salt to nitrous acid. The        stronger acids may be included in that phase so that the pH of        the mixed system is in a range to both optimize the efficacy of        the salicylic and mandelic acids (higher keratolytic and/or        antimicrobial activity balanced against skin irritancy        potential), as well as to ensure that the nitrous acid that is        formed in the mixed matrix is at a balanced (nitrous        acid/nitrite) ratio to ensure the desired efficacy and stability        of the nitrous acid. The equilibrium this refers to is shown in        the following relationship, wherein the pH determines the        balance:

Na⁺NO₂ ⁻←±H⁺→HONO+Na⁺

The inventor has discovered that the nitrous acid system, when adjustedto a desired level of solution acidity, is capable of a remarkabledegree of antimicrobial activity. The following table shows thecorrelation between pH and degree of conversion of nitrite ion tonitrous acid. The balance of the species will determine the germicidalcapability of the system; the higher the pH the lower the activity butthe greater the solution stability, and the lower the pH the greater theactivity but the lower stability.

TABLE 1 Percentage of Nitrite as Nitrous Acid at Varying pH Values pHNitrous Acid % Nitrite % 1.5 98.4 1.6 2.0 95.2 4.8 2.3 90.9 9.1 2.6 83.316.7 2.8 76.0 24.0 3.0 66.7 33.3 3.3 50.0 50.0 3.5 38.8 61.2 4.0 16.683.4 4.5 6.0 94.0 5.0 2.0 98.0Aqueous solutions of nitrous acid are unstable, and decompose accordingto the following equation. Instability increases with increased absoluteand relative molar concentrations of the HONO, and with increasing heat:

3HNO₂(aq)←→H⁺(aq)+2NO(g)+NO₃ ⁻(aq)+H₂O(l)

3HNO₂(aq)←→H⁺(aq)+2NO(g)+NO₃ ⁻(aq)+H₂O(l)  Equation 1

The reaction is a combination of the two half-reactions, as follows:

2{HNO₂+H⁺ +e ⁻←→--->NO+H₂O}  Equation 2

ε°=1.00 volts

HNO₂+H₂O←→NO₃ ⁻+3H⁺+2e ⁻  Equation 3

ε°=−0.94 volts

Σ=3HNO₂(aq)←→H⁺(aq)+2NO(g)+NO₃ ⁻(aq)+H₂O(l)⁻

In addition to the concentration-dependent degradation of nitrous acid,as shown above, nitrous acid will also act as an oxidizing agent in thepresence of oxidizable materials, such as microorganisms, according tothe first half-cell reaction above (Equation 2), with a redox potentialε°=1.00 volts. Accordingly, nitrous acid systems are quite destructiveof all classes of microorganisms which are susceptible to oxidation,including bacteria, yeasts, molds and viruses. This destruction is wellknown for other non-specific oxidizing germicides such as bleach(hypochlorous acid), chlorous acid, chlorine dioxide, and iodine. Indeedmicrobiocidal data developed by an independent laboratory on a pre-mixedtypical formula of the inventive composition show the outstandingcapacity of a system comprised of nitrous, mandelic, and salicylicacids, which outperforms, by many orders of magnitude, the antimicrobialactivity of well-regarded commercial acne treatment formulations. Thesedata, and the formulation from which they were obtained, are provided inExample 1 of the instant disclosure.

It should be noted that the U.S. Food & Drug Administration allows thesale of over-the-counter acne drugs under 21 C.F.R. Part 333, “TopicalAcne Drug Products for Over-the-Counter Human Use.” Under 37 C.F.R.§333.310, Acne active ingredients: (a) lists salicylic acid 0.5 to 2percent. Salicylic acid, by its very nature as a keratolytic agent, hasan inherent skin irritancy, as do all the other α-hydroxy acids. Indeveloping an effective acne composition, it is important therefore toestablish a pH for the formulation that provides sufficient of thesalicylic acid in its unionized form

to dissolve the skin tissue. The ionized salicylate form

has no such activity. The pH for these inventive compositions is ofgreat significance. A pH should be chosen for both the Part A alone andthe Part B alone, as well as the pH of the resulting mix, such that theyindividually, and upon combination, are of optimum efficacy, stability,and of minimum irritation potential.

Part A Considerations:

The antimicrobial and the keratolytic activities of the three acidcomponents (at least two (e.g., salicylic and mandelic acids) from PartA and the third formed upon combination of Parts A and B (i.e., nitrousacid)), either after pre-mixing or sequential mixing one the subject'sskin, is significantly dependent on the relative amount of the free acidform of each of the particular compounds vis-à-vis its inactive saltform.

The pK_(a) of salicylic acid is 2.97, which means that when salicylicacid is a component of an aqueous composition at a pH of about 3.0,one-half of that compound will exist in the active keratolytic acid formand one-half will be present in the inactive salt form. It is generallyrecommended that a salicylic acid-based acne treatment composition havea pH in the range of from about 3.0 to about 3.5. The lower the pH thegreater the potential efficacy, but also the greater potentialirritation. To put this into perspective, whereas at pH 3.0 there is a˜50:50 ratio of active and inactive (acid:salt) forms, at a pH of about3.5, the ratio of acid:salt forms drops to about 25:75. And at a pH of˜3.3, the ratio is about 33:67. The relative amounts will constitutepart of the considerations when formulating compositions based on thisinventive disclosure.

The same consideration of activity vs. acid:salt forms applies tomandelic acid, where the antimicrobial activity of an aqueous solutioncontaining this material is strongly dependent on the pH of the system.Mandelic acid is inherently a weaker acid than salicylic acid, having apK_(a) of 3.41. Thus at pH levels common to commercial salicylic acidformulations, generally at pHs of about 3.0 to about 3.5, there will bea significant fraction of the mandelic acid available for germicidalactivity, i.e., about 45% to about 70% as free acid, as seen shownbelow:

Percentage of Mandelic Acid in Acid and Salt forms at Varying pH ValuespH Mandelic Acid % Mandelate % 2.46 90 10 2.81 80 20 3.04 70 30 3.23 6040 3.41 50 50 3.59 40 60 3.78 30 70 4.01 20 80

And of notable coincidence, the same pH range is optimum for thegermicidal activity of nitrous acid, when the inventive compositions areadjusted to pH values from about 3.0 to about 3.5, upon combination ofParts A and B. This pH range applies to both the premixed A+Bcomposition, or to the pH that obtains when the parts are appliedsequentially to the skin, either Part A then Part B, or Part B then PartA. (The pH of the sequentially applied mixture on the skin is assumed tobe that for the premixed A+B phases.) A section of the acid:salt formtable, shown previously for nitrous acid as a function of pH, isprovided below, to bracket pH ranges appropriate to the inventivecompositions disclosed herein.

Percentage of Nitrite as Nitrous Acid at Varying pH Values pH NitrousAcid % Nitrite % 2.8 76.0 24.0 3.0 66.7 33.3 3.3 50.0 50.0 3.5 38.8 61.24.0 16.6 83.4As is evident from this tabulation, by adjusting the pH of the inventivecomposition to a range, upon combination of Parts A and B. to about 3.0to about 3.5, the nitrous acid generated upon their combination willrepresent from about 40% to almost 70% of the nitrite moiety in the freeacid (germicidal) form. This has been determined to be an optimum rangefor the relative stability of the metastable nitrous acid that is formed(the species responsible for the high germicidal activity) whichserendipitously overlaps both the active ranges of both mandelic andsalicylic acids, in their respective roles as germicidal andgermicidal+keratolytic agents, at acidities where skin irritation isconsidered to be of minimal concern. The inventor has seen, from earlierinvestigations of nitrous acid germicidal systems, that the longer-rangestability of nitrous acid systems is significantly diminished when theHONO (nitrous acid) form of the nitrite system exists in ratios of >˜2:1acid/salt. The disproportionation of nitrous acid proceeds too rapidly,with a significant evolution of NO, and loss of desired germicidalreserve (see, Equation 1 above.) Contrary to common belief, the NOmolecule is not highly germicidal, and it has been evident to thisinventor that, even when all the NO of an activated nitrite system hasbeen lost by evaporation and/or by reaction with oxygen to form the N₂O₄molecule, the high germicidal action of acidified nitrite systemsremains at equal, or even greater activity than the original mixture (asmore H⁺ is slowly generated [see Equation 3], creating more HONO thaninitially.)

As implied by the above, the desired pH range of from about pH 3 toabout pH 3.5, for these inventive compositions, upon combination of bothParts A and B (premixed or sequentially applied), must be achieved bydue consideration of the initial pH values of the individual Parts A andB, and such other factors as the buffering capacity of each part, andthe relative volumes of each part when the two parts are combined. Ingeneral, the presence of the two α- and β-hydroxy acids, preferablymandelic and salicylic acids, which can function to buffer the pH of theA phase, will play a strong role in maintaining the pH of the combinedsystem relatively close to the initial pH of part A, assuming thefollowing:

-   -   The relative volumes of Parts A and B, in the intended use of        the inventive composition, approximate 1:1. In certain        circumstances, where the desired volume for one of the parts        (more likely for Part B), the higher the relative volume of Part        B the greater the tendency for an elevation of the pH of the        combination (see detailed consideration of the Part B        composition in the following section.)    -   The composition of Part B. There is little need for a pH much        above pH 7.5-8.5, simply to ensure the stability of the nitrite        salt. As will be seen, there are a number of optional materials        that can be included in part B, to provide further benefit to        the inventive composition in addition to it being a source of        the powerful nitrous acid germicide, which forms upon        combination with part A. A person skilled in the arts of        chemistry and so-called cosmeceuticals will be familiar with        those beneficial skin components that are stable in the mildly        alkaline environment of part B.

It will be recognized that the acidity associated with a part A+Bmixture, with a stipulated pH of about 3.0→3.5, refers to a H⁺concentration approaching 4 logs (10,000) below neutrality (pH=7.)Consider that a Part B formulation at, for example, pH=8, is one log(10) above neutrality, so even without considering any Part A bufferingcomponents, a Part A solution in the pH=3 range has 1,000-fold greatercapacity to neutralize any alkaline source in Part B, with minimumimpact on overall pH. Consistent with these considerations, I havedetermined that the various typifying Part B formulations shown in thefollowing Examples have a relatively limited impact on the pH of theinventive, mixed compositions. As a result, the pH of the Part Aformulation will generally be significantly different from the A+B mixpH, after due consideration of any dilutive effects by the Part Bcomposition. Of course should other Part B components be found to bebeneficial partners in this disclosed A+B inventive composition, whereinthe Part A formulation has an initial pH significantly below that of themixed composition, then a skillful practitioner would have littledifficulty in making the appropriate adjustment to achieve the samestipulated mix pH range.

With respect to the levels of inclusion of both salicylic and theα-hydroxy acid in Part A where mandelic acid is the α-hydroxy acid in apreferred embodiment, the following considerations apply.

-   -   Regarding salicylic acid, its concentration, in the combined        formulation, should lie in the range of from about 0.5% to about        5.0%. In the circumstance where the part A is applied to the        skin prior to the application to part B, the concentration of        salicylic acid in part A should not exceed 2.0%. This is        consistent with the US FDAs monograph covering the sale of OTC        acne drugs under 21C.F.R. Part 333 “Topical Acne Drug Products        for Over-the-Counter Human Use.” Under §333.310, Acne active        ingredients. (a) is listed Salicylic acid 0.5 to 2 percent. When        the alternate sequence of application is followed, namely part B        then part A, the concentration of salicylic acid in the        composition which forms upon their mixture on the skin, by        physical means (such as finger tips or a cotton swab), should        not exceed the stipulated 2.0%. Similar considerations apply        with respect to the lower use level for salicylic acid, where        adjustments are made in the selection of the designated 0.5%        lower concentration limit contingent upon the sequence of        application and, of course, the relative volumes of the two        parts to be applied.    -   Regarding the α-hydroxy acid in Part A, excluding mandelic acid        and its preferred embodiment: In general its concentration, in        the combined formulation, should lie in the range of from about        0.5% to about 5.0%. When the inventive technology is for use in        topical applications other than for acne vulgaris, a variety of        α-hydroxy acids may be used, all of which have antimicrobial        activity in addition to their recognized keratolytic properties.        These include mandelic, glycolic, lactic, malic, citric, and        tartaric acids. As discussed below, the inventive compositions,        including any or many of these acids, have good efficacy in the        treatment of a variety of skin conditions. For the treatment of        acne vulgaris, an exception is made, requiring the avoidance of        glycolic and lactic acids, in these compositions. And with the        exception of those two acids, the stipulated pH range of the        mixed formulation, irrespective of sequence of application or        pre-mixed, should be about 3.0 to about 3.5. The U.S. Food &        Drug Administration requires keratolytic products containing        glycolic and/or lactic acids to have pH values≧pH 3.5. For        emphasis of the foregoing, compositions of this inventive        disclosure which are intended for use for skin afflictions other        than for acne vulgaris, may be prepared where the pH range of        the A+B combination can have the same pH in the 3.0→3.5 range.        Practically speaking the use of lactic and/or glycolic acid in        this disclosure for the treatment of acne vulgaris is        contraindicated.

With specific reference to mandelic acid, as the sole or one of severalα-hydroxy acids in Part A, in a preferred embodiment, its level ofinclusion in Part A should be dictated by the desired level in the mixedcombination of parts A and B, irrespective of whether Parts A and B arepremixed, or applied to the subject's skin sequentially, in either thePart A then Part B, or the Part B then Part A order. The desired levelof mandelic acid in that mixed combination should lie the inconcentration range of from about 0.2% to about 5.0% range, in apreferred range of from about 0.5% to about 2.5%, and in a mostpreferred range of from about 0.75% to about 2.0% concentration. Thisapplies to the use of the inventive composition for the topicaltreatment of both acne vulgaris and other skin afflictions.

As part of the foregoing disclosure, the primary focus was directed tothe source of the additional strong germicidal activity provided by thenitrite salt, upon combination with the Acidic A phase. As furtherdescribed herein, it is pointed out that a mild alkaline medium is allthat is required for the nitrite salt to have an appropriate long-termstability. That generally should be in the pH range from about 7.0 toabout 9.0. There is no reason that the upper limit cannot be extended tohigher pHs, although this would then require an appropriate level ofadditional activating acid to reduce the nitrite to the general mixrange of a pH of about 3.0 to about 3.5. That activating acid does notnecessarily have to be either the salicylic or mandelic acid, in thepreferred embodiment, and the H⁺ requirement could readily be providedby, for example, a stronger mineral acid. The lower limit for stabilityof the nitrite salt could actually extend below pH 7.0, to about pH 6.5.

Other beneficial agents can be incorporated into phase B, where the termbeneficial applies to qualities which impart both a) physical; and b)physiological qualities. In the former “a” category are includedtextural qualities, e.g., viscosity modifiers (see more detailed sectionbelow), surfactancy qualities e.g., non-ionic and anionic surfactants,appearance and coloration, pH adjustment and buffering e.g., sodiumcarbonate which forms sodium bicarbonate. In category “b” are includedthose materials which impart beneficial qualities to the skin e.g.,allantoin and silicone-compounds providing smoothness. The selection andlevel of use of these materials are well known to those who are familiarwith cosmetic formulation development.

With regard to the level of use of the nitrite salt, as represented bysodium nitrite in the following range specification, it has been foundthat appropriate levels of supplemental germicidal activity can beachieved (on the basis of a 1:1 volume use of Parts A and B) with levelsof sodium nitrite in B from about 0.2% to about 5.0%, preferably in therange of about 0.4% to about 2.5%, and most preferably in the range ofabout 0.75% to about 1.5%. With other soluble nitrite salts, such aspotassium nitrite, the weight ranges should be suitably adjusted. Itshould be again noted, that the intended ratio of Parts A and B, mixedprior to application or ad seriatim, must be taken into consideration inregard to both achieving the corresponding concentrations of the nitritesalt, and the desired mix pH of the inventive composition in theapproximate pH range of from about 3.0 to about 3.5. With regard to theconcentration ranges of the nitrite salt in Part B, their levels shouldbe adjusted up or downwards, depending on the relative use ratios of theA/B combination. In general, the higher the relative amount of Part A,the higher the relative concentrations of the nitrite salts, inproportion to the use ratio of A and B parts. And the opposite situationapplies if the ratios are reversed.

With regard to pH, if the pH of the B phase in a particular formulationis, e.g., say, 8.5, and it is desired for example to first apply onepart of A, on a random small set of acne blemishes on a subject's face,and thereafter apply a relatively larger three parts of B over theentire face, so as to deposit certain beneficial agents onto the skin,then the acidity and alkalinity of parts A and B, respectively, shouldbe adjusted initially so that the mix pH of 1A:3B falls within thestipulated range of about pH 3.0→3.5. It should be obvious, to those whopractice in the arts of cosmetic and cosmeceutical chemistry, that dueconsideration must be paid to the viscosity of each component, asdiscussed hereinafter, when determining the relative volumes of Parts Aand B intended to be applied, in any of the ways described.

Other objects and features of the present invention will become apparentwhen considered in combination with the following detailed descriptionof the invention, which provides certain preferred embodiments andexamples of the present invention. It should, however, be noted that theaccompanying detailed description is intended to discuss and explainonly certain embodiments of the claimed invention and is not intended asa means for defining the limits and scope of the invention.

DETAILED DESCRIPTION OF ADDITIONAL PREFERRED EMBODIMENTS

In the application of this technology, it is often preferable toincorporate a thickening (gelling) agent to one or both parts of thetwo-part system, to add “body” to the composition. This allows for agreater deposition of the mixed material to skin surfaces, and a greaterduration of action. Gelling agents for use in the present inventioninclude polysaccharides extracted from legume seeds, such as thegalactomannans, including guar gum and locust bean (carob) gum. Othergelling agents include high molecular weight polyoxyalkylene crosslinkedacrylic polymers as well as the highly preferred cellulosics such ashydroxymethyl cellulose, hydroxypropyl cellulose, hydroxyethylcellulose, methyl cellulose, methylpropyl cellulose, among others,including high molecular weight polyethylene glycols, polyacrylamide andpolyacrylamide sulfonates, and crosslinked polyvinylpyrrolidones, amongothers.

As indicated in the title of this inventive composition,“Multifunctional Topical Formulation for the Treatment of Acne Vulgarisand Other Skin Conditions,” there are a variety of othermicrobially-associated skin disorders which can benefit substantiallyfrom the application of compositions incorporating the inventivepowerful topical antibacterial technology. These conditions, asreferenced in Section 2. Description of the Related Art, include a hostof other skin afflictions where microbial proliferation is a majorproblem. Examples in the category of bacterial skin infections andrelated conditions are boils, folliculitis, carbuncles, furuncles,cellulitis, abscesses, impetigo, and erysipelas. There is indeed a greatneed for an antimicrobial composition to treat diabetic foot ulcers,which result from deficient blood flow to peripheral tissues, such as inthe feet of diabetes sufferers, where the necrotic tissue becomes asource of nutrients to invading bacteria. These often lead to footamputation. There is the intriguing possibility, in such cases, that thenitrous oxide, NO, which is generated from nitrous acid degradation, asshown earlier in this Specification (3HNO₂←→H⁺+2NO+NO₃ ⁻+H₂O) canpenetrate to the underlying capillaries and stimulate their dilation,leading to enhanced blood flow, thereby helping to counter the ischemiaresulting from diminished oxygen supply to the affected tissues. Also ofpotential benefit from the inventive technology are those afflictionsrelated to common fungal infections, including athlete's foot, jockitch, ringworm, and yeast infections.

The present invention is illustrated by the following Examples. Allparts and percentages therein, as well as the Specification and claims,are by weight, unless otherwise specified. The following examples, whichare non-limiting, further describe preferred embodiments within thescope of the present invention. Many variations of these Examples arepossible without departing from the spirit of the invention.

Example 1

Example 1 demonstrates the antimicrobial activity of a formulation inwhich Parts A and B were mixed together immediately prior to theirevaluation against the gram-positive aerotolerant, anaerobic bacteriumPropionibacterium acnes (P. acnes) that is associated with acne. Theformulas for Parts A and B of this inventive composition were asfollows:

Part A:

COMPONENT Percentage Isopropyl alcohol (70%) 35.70 Sodium benzoate 0.04Salicylic acid 1.00 Mandelic acid 1.00 Pluronic P103 0.10 Propyleneglycol 10.00 Natrosol 250MR 2.10 (hydroxyethylcellulose) Titaniumdioxide (fine) 0.10 Deionized water 49.96 pH adjusted to ~2.8 with conc.NaOH

Part B:

COMPONENT Percentage Pluronic P103 0.1 Dodecylbenzene sulfonate, Na⁺ 0.1Sodium Nitrite (pure basis) 1.0 NaOH (10N) ~2.2 Carbopol 980 1.0Titanium dioxide (fine) 0.1 Deionized Water ~95.5 pH adjusted to ~8.5 -The pH of the mixed composition was 3.25The microbiological results from testing this freshly mixed compositionon the P. acnes bacterium, were as follows:

Test Organism: P. acnes ATCC 6919

Initial Suspension: 2.3×10⁷

Challenge Inoculum Recovered Log Test Sample (Log#cfu/ml) (Log#cfu/ml)Reduction Inventive 2.3 × 10⁶ 0 >>5.36 Composition (6.36) (0)rdk110PGX235 A + B Acne Free ™ 2.3 × 10⁶ >1 × 10⁴* <<2.5  Terminator 10(6.36) (>>4.0) Proactiv Solution ® 2.3 × 10⁶ >1 × 10⁴* <<2.5  (Rodan and(6.36) (>>4.0) Fields) Control (Saline) 2.3 × 10⁶ 2.3 × 10⁶  (6.36)*Approximate Minimum CountIt can be noted, from the Log Reduction data, that the efficacy of aspecific formulation of the inventive composition is at least 1,000times (>3 logs) greater than any of these commercial products, andparticularly that approximately 6 logs (1 million) of organisms, per mlof test medium, were destroyed within one minute of contact with thisrepresentative formulation of the inventive composition. The other twocommercial formulations, each of which contain 2% of salicylic acid ascf. the 0.5% salicylic acid in the mixed composition, showed nosignificant reduction of the P. acnes organism count, after the60-second contact. This is not unexpected because the primary focus ofthese two commercial products was on the acne pustules, papules, etc.,rather than the microorganism that is invariably present on the skin ofacne patients, as a probable exacerbant of their skin affliction.

Example 2

Example 2 illustrates the efficacy of the formulation shown in Example 1in the treatment of acne-afflicted subjects. It was a “prospective,comparative, randomized clinical study” involving twenty-three femaleand twenty-one male individuals, aged 9-29; twenty-two of whom hadlesions on their faces, chests and backs; twelve on their faces only;and ten on their faces and backs. The patients were randomly divided intwo groups, as follows:

Control:

Conventional treatment with systemic antibiotics and topical retinoids;

Experimental:

Topical treatment of the lesions with the premixed test formulation,twice a day for up to 4 weeks, with photos taken every week.

The following summary of findings was provided by the clinician whocoordinated the study:

-   -   The new treatment had the same efficacy as the conventional        treatment    -   The advantage is that the new treatment is potentially safer    -   Conventional treatment is based on systemic antibiotics given        for long periods and retinoids. Long term antibiotics can        disrupt endogenous normal flora, and retinoids have been        associated with hypertriglyceridemia and a high risk of suicide        in adolescents

Example 3

Example 3 illustrates the efficacy of the formulation shown in thetreatment of acne-afflicted subjects, when the Part A component is firstonly applied to the individual acne blemishes, and then the Part Bapplication follows shortly thereafter, uniformly spread over the wholeskin area where the acne is evident. The application of the Part Acomponent is done by fingertip to the individual spots, while the Part Bapplication is accomplished with a cotton swab. The Part A formulationhas a higher viscosity, by virtue of inclusion of a Natrosol thickenerin its composition. Part B, which is activated to form nitrous acidprimarily at the site of the acne infections, has a lotion-promotingcomponent (Sepigel) which is often found in such types of formulations.The Part B also contains Allantoin, which is recognized by cosmeceuticalchemists to stimulate healthy, normal tissue formation. It has beenclassified by the FDA as an over-the-counter, Category I (safe andeffective) active ingredient skin protectant.

Part A:

COMPONENT Percentage Isopropyl alcohol (70%) 35.70 Sodium benzoate 0.04Salicylic acid 1.00 Mandelic acid 1.00 Pluronic P103 0.10 Propyleneglycol 10.00 Natrosol 250HHR 1.30 (hydroxyethylcellulose) Blue #1 0.1%solution 0.05 Deionized water 50.290 Sodium Hydroxide 20% soln 0.52 pHof part A formulation was 3.42

Part B:

COMPONENT Percentage Pluronic P103 0.10 Dodecylbenzene sulfonate, 0.10Na⁺ Sodium Nitrite (pure basis) 1.00 NaOH (20% solution) 0.05 Sepigel305 0.25 Allantoin 0.10 Xanthan Gum 0.10 Deionized Water 98.30 pHadjusted to ~8.5

A number of young men and women, who had acne outbreaks on their skin,had applied this inventive composition ad seriatim, where the Part A wasallowed to remain for a few minutes prior to smoothing on the Part B, asdescribed above. They all reported that the individual acne blemisheshad cleared within several days of application of this composition on a2×/day basis.

Example 4

Example 4 illustrates the efficacy of the formulation shown in Example 1in the treatment of non-acne skin conditions. Within several days oftwice per day application of the mixed formulation, one individual withintractable folliculitis reported a remarkable reduction of the inflamedarea, which theretofore was resistant to a variety of other medications.A young woman with widespread acne covering her upper torso and face, toa degree that she avoided appearing in public areas, had applied thecomposition twice a week to the affected areas. After one month thecondition had completely disappeared. She also had suffered frompityriasis alba, which also was no longer evident one month after thetwice-per-week application.

While only several embodiments of the present invention have been shownand described, it will be obvious to those skilled in the art that manymodifications may be made to the present invention without departingfrom the spirit and scope thereof.

1-14. (canceled)
 15. A method for treating acne vulgaris, comprising thesteps of: formulating an acidic aqueous solution having salicylic acidand an α-hydroxy acid with the α-hydroxy acid concentration being in therange of from about 0.5% to about 5.0% and with said acidic aqueoussolution having no lactic acid and no glycolic acid; formulating analkaline aqueous solution having an alkaline nitrite salt; mixingtogether said acidic aqueous solution and said alkaline aqueous solutionfor forming a two-part aqueous composition; and, applying said acidicaqueous solution and said alkaline aqueous solution to a portion of skinof a patient by applying said two-part aqueous composition for treatingacne vulgaris afflicting the portion of skin. 16-20. (canceled)
 21. Themethod for treating acne vulgaris according to claim 15, wherein saidacidic aqueous solution includes an α-hydroxy acid selected from thegroup consisting of malic acid, mandelic acid and a combination thereof.22. The method for treating acne vulgaris according to claim 15, whereinsaid alkaline aqueous solution includes said alkaline nitrite salt ofsaid alkaline part is sodium nitrite.
 23. The method for treating acnevulgaris according to claim 15, wherein said two-part aqueouscomposition has a pH in the range of about 3.0 to about 3.5.
 24. Amethod for treating acne vulgaris, comprising the steps of: formulatingan acidic aqueous solution having salicylic acid and mandelic acid, saidacidic aqueous solution having no lactic acid and no glycolic acid;formulating an alkaline aqueous solution having an alkaline nitritesalt; mixing together said acidic aqueous solution and said alkalineaqueous solution for forming a two-part aqueous composition having aconcentration of salicylic acid in the range of from about 0.5% to about5.0%; and, applying said acidic aqueous solution and said alkalineaqueous solution to a portion of skin of a patient by applying saidtwo-part aqueous composition for treating acne vulgaris afflicting theportion of skin.
 25. The method for treating acne vulgaris according toclaim 24, wherein said acidic aqueous solution includes an additionalα-hydroxy acid.
 26. The method for treating acne vulgaris according toclaim 25, wherein said additional α-hydroxy acid is malic acid.
 27. Themethod for treating acne vulgaris according to claim 24, wherein saidalkaline aqueous solution includes said alkaline nitrite salt of saidalkaline part is sodium nitrite.
 28. The method for treating acnevulgaris according to claim 24, wherein said two-part aqueouscomposition has a pH in the range of about 3.0 to about 3.5.